DCGen (디시젠)
Seoul, South Korea
DCGen is a genomic analysis technology company that offers OncoFREE, an in-vitro diagnostics multivariate index assay (IVD-MIA) which predicts prognosis based on the risk for distant metastasis in hormone receptor-positive, HER2-negative early-stage breast cancer patients with no axillary lymph node metastasis, by analyzing breast cancer tissue RNA expression data; and HOPE, a test that determines the risk for developing hereditary cancer.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2017
- Website
- www.dcgen.co.kr/
Only accessible to MedStartr community members.
Join nowWhat do you think of DCGen (디시젠)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now